BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis

Abstract excerpt

Despite significant improvements in treatment, cure rates for many cancers remain suboptimal. The rise of cytotoxic chemotherapy has led to curative therapy for a subset of cancers, though intrinsic treatment resistance is difficult to predict for individual patients. The recent wave of molecularly targeted therapies has focused on druggable-activating mutations, and is thus limited to specific subsets of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer-related Molecular Pathways
• Share to Cell death mechanisms and regulation
• Share to PARP inhibition in cancer therapy